Short Interest in Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Rises By 230.8%

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 8,600 shares, a growth of 230.8% from the December 15th total of 2,600 shares. Based on an average daily volume of 362,400 shares, the days-to-cover ratio is presently 0.0 days.

Oncotelic Therapeutics Trading Up 22.8 %

Shares of OTCMKTS OTLC opened at $0.04 on Tuesday. Oncotelic Therapeutics has a fifty-two week low of $0.02 and a fifty-two week high of $0.05. The firm has a market capitalization of $14.22 million, a P/E ratio of -3.50 and a beta of -0.27. The company has a debt-to-equity ratio of 0.28, a current ratio of 0.01 and a quick ratio of 0.01. The company’s 50 day simple moving average is $0.03 and its 200 day simple moving average is $0.03.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.